Clinical Pharmacokinetics and Pharmacodynamics¶
Rowland, M., & Tozer, T. N. (2011). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Wolters Kluwer.
Cited by¶
13 citations across 13 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Bioavailability
- Across a multi-stage path it is approximately the product of per-stage retention fractions.
This sourceStandard pharmacokinetics text defining bioavailability F as the fraction of an administered dose reaching systemic circulation in active form, F = AUC_oral/AUC_IV with IV defined as 100%, F ≈ f_a·f_g·f_h as the product of per-stage retentions, and the consequences for oral-versus-IV dose equivalence and high-extraction-ratio drugs.
- Across a multi-stage path it is approximately the product of per-stage retention fractions.
- Clearance Rate
- A kinetic regime: clearance is typically first-order, proportional to current stock and producing exponential decay with a definite half-life, or zero-order, a fixed maximum rate that saturates while excess accumulates, with mixed regimes in between.
This sourceStandard text on clearance, first-order versus zero-order (Michaelis–Menten) kinetics, half-life, steady state, and dose adjustment for organ impairment.
- A kinetic regime: clearance is typically first-order, proportional to current stock and producing exponential decay with a definite half-life, or zero-order, a fixed maximum rate that saturates while excess accumulates, with mixed regimes in between.
- Loading Dose
- In pharmacology, the origin, a drug with a long half-life is started with a single loading dose to reach therapeutic concentration in hours instead of days, after which ongoing doses balance clearance.
This sourceLoading dose = C_target x V_d and maintenance rate = C_target x CL under first-order one-compartment kinetics, with the exponential approach to steady state set by the elimination half-life and the overshoot hazard of an oversized bolus.
- In pharmacology, the origin, a drug with a long half-life is started with a single loading dose to reach therapeutic concentration in hours instead of days, after which ongoing doses balance clearance.
- PK/PD Modeling (Pharmacokinetics / Pharmacodynamics)
- PK/PD modeling is the coupled mathematical framework for characterizing what the body does to a drug (pharmacokinetics, PK — absorption, distribution, metabolism, excretion) and what the drug does to the body (pharmacodynamics, PD — the concentration-response relationship at the site of action), with the coupling providing a dose→concentration→effect pipeline that is the central quantitative apparatus of clinical pharmacology, as Rowland and Tozer (2010) develop in their canonical treatment of clinical pharmacokinetics and pharmacodynamics.
This sourceLippincott Williams & Wilkins. Standard pharmacokinetics text: develops compartment-model decay of drug plasma concentration as a signal-level phenomenon distinct from chronic system-level functional decline.
- PK/PD modeling is the coupled mathematical framework for characterizing what the body does to a drug (pharmacokinetics, PK — absorption, distribution, metabolism, excretion) and what the drug does to the body (pharmacodynamics, PD — the concentration-response relationship at the site of action), with the coupling providing a dose→concentration→effect pipeline that is the central quantitative apparatus of clinical pharmacology, as Rowland and Tozer (2010) develop in their canonical treatment of clinical pharmacokinetics and pharmacodynamics.
- Rate Limiting
- The token-bucket insight that a bucket admits bursts up to its size then averages to its refill rate transfers to pharmacology: a loading dose followed by maintenance dosing is the same shape, with bucket size as the loading dose, refill rate as the maintenance dose, and leakage as pharmacokinetic clearance.
This sourceStandard text on dose regimens: a loading dose rapidly fills the body's drug 'budget' and a maintenance dose replenishes it against clearance — the pharmacokinetic analogue of bucket size, refill rate, and leakage.
- The token-bucket insight that a bucket admits bursts up to its size then averages to its refill rate transfers to pharmacology: a loading dose followed by maintenance dosing is the same shape, with bucket size as the loading dose, refill rate as the maintenance dose, and leakage as pharmacokinetic clearance.
- Signal Decay and Fadeout
- A patient on a fixed antibiotic dose experiences signal decay (drug concentration diminishes, efficacy weakens) while the drug itself remains chemically unchanged; the system (the patient's body) is the environment in which the signal (drug molecules) decays, a clinical consequence Rowland and Tozer (2010) develop systematically through compartment-model pharmacokinetics.
This sourceLippincott Williams & Wilkins. Standard pharmacokinetics text: develops compartment-model decay of drug plasma concentration as a signal-level phenomenon distinct from chronic system-level functional decline.
- A patient on a fixed antibiotic dose experiences signal decay (drug concentration diminishes, efficacy weakens) while the drug itself remains chemically unchanged; the system (the patient's body) is the environment in which the signal (drug molecules) decays, a clinical consequence Rowland and Tozer (2010) develop systematically through compartment-model pharmacokinetics.
- Washout Failure
- A unit is held under condition \(A\), which induces a state \(s\) that, after \(A\) is removed, decays as \(s(t) = s_0 e^{-t/\tau}\) with half-life \(t_{1/2} = \tau \ln 2\).
This sourceStandard source for first-order (mono-exponential) elimination C(t)=C0 e^(-kt) with half-life t_{1/2}=ln 2 / k — the textbook decay identity used here.
- A unit is held under condition \(A\), which induces a state \(s\) that, after \(A\) is removed, decays as \(s(t) = s_0 e^{-t/\tau}\) with half-life \(t_{1/2} = \tau \ln 2\).
Domain-specific¶
- Absorption Phase
- Within the standard ADME framework (Absorption, Distribution, Metabolism, Excretion), the absorption phase localises a specific set of determinants: membrane permeability, dissolution rate in the relevant fluid, carrier-mediated transport, blood flow to the administration site, and first-pass extraction (primarily hepatic and intestinal) that removes a fraction of the dose before it reaches the systemic compartment
This sourceThe first-order absorption model summarised by the rate constant k_a and the bioavailable fraction F as the two parameters of the absorption phase. Absolute bioavailability is defined against an intravenous reference for which F = 1 by definition, the dose being placed directly in the systemic circulation.
- Within the standard ADME framework (Absorption, Distribution, Metabolism, Excretion), the absorption phase localises a specific set of determinants: membrane permeability, dissolution rate in the relevant fluid, carrier-mediated transport, blood flow to the administration site, and first-pass extraction (primarily hepatic and intestinal) that removes a fraction of the dose before it reaches the systemic compartment
- Clearance
- This concentration-independence makes clearance additive across parallel elimination pathways: Cl_total = Cl_renal + Cl_hepatic + Cl_biliary + Cl_other, each term reflecting that organ's extraction ratio times its blood flow
This sourceClearance as concentration-independent under first-order kinetics, hence additive across parallel eliminating organs, with each organ's clearance equal to its blood flow times its extraction ratio. Renal dose adjustment as clearance-proportional reduction of the maintenance dose, the principle underlying renal dosing tables for predominantly renally eliminated drugs.
- This concentration-independence makes clearance additive across parallel elimination pathways: Cl_total = Cl_renal + Cl_hepatic + Cl_biliary + Cl_other, each term reflecting that organ's extraction ratio times its blood flow
- Elimination Pathway
- Renal elimination — hydrophilic drugs (gentamicin, lithium, vancomycin) cleared by glomerular filtration and tubular secretion
This sourceStandard text on renal drug handling as the net of glomerular filtration, active tubular secretion of organic acids and bases, and tubular reabsorption - the framework needed to classify the three named drugs correctly.
- Renal elimination — hydrophilic drugs (gentamicin, lithium, vancomycin) cleared by glomerular filtration and tubular secretion
- Elimination Rate Constant
- Volume of Distribution
- Listed in the references but not attached to a specific claim.
Mechanisms¶
- Validity Boundary Scan
- But as the dose climbs, the liver's metabolizing enzymes begin to saturate — clearance follows Michaelis–Menten kinetics,
This sourceExplains that saturable metabolism follows Michaelis–Menten kinetics toward a maximum rate, producing nonlinear clearance and disproportionate accumulation as dose rises.
- But as the dose climbs, the liver's metabolizing enzymes begin to saturate — clearance follows Michaelis–Menten kinetics,
Verification¶
Does it exist? Confirmed. This work's ISBN resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Not recorded. Neither this nor any other of the 13 citations of this work carries a recorded support check.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Links previously used in the corpus¶
Before the registry existed this work was also linked 4 other ways.
- https://search.worldcat.org/title/427509167 ×1
- https://shop.lww.com/Clinical-Pharmacokinetics-and-Pharmacodynamics/p/9780781750097 ×1
- https://shop.lww.com/p/9781496385048 ×1
- https://www.worldcat.org/title/clinical-pharmacokinetics-and-pharmacodynamics-concepts-and-applications/oclc/644836509 ×1
Registry ID ref:c19c31c41d52 · see in the full table